

Appendix: Tables

1.	Sales January to December 2025 and 2024	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2025 vs. YTD December 2024	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the twelve months ended 31 December 2025	11
10.	Roche Group core results reconciliation – Full Year 2025	12
11.	Divisional core results reconciliation – Full Year 2025	13
12.	Roche Group consolidated balance sheet.....	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to December 2025 and 2024

CHF millions	Twelve months ended 31 December		% change	
	2025	2024	At CER	In CHF
Pharmaceuticals Division	47,669	46,171	9	3
United States	25,355	24,774	8	2
Europe	9,164	8,832	5	4
Japan	2,882	2,874	5	0
International	10,268	9,691	14	6
Diagnostics Division	13,847	14,324	2	-3
Roche Group	61,516	60,495	7	2

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Pharmaceuticals Div.	11,914	12	11,949	8	12,036	11	11,570	7	12,114	9
United States	6,608	15	6,224	6	6,446	13	6,128	5	6,557	9
Europe	2,219	10	2,320	5	2,246	5	2,252	5	2,346	7
Japan	791	1	671	3	754	7	714	6	743	4
International	2,296	11	2,734	18	2,590	11	2,476	11	2,468	16
Diagnostics Division	3,597	-1	3,491	0	3,468	0	3,348	2	3,540	6
Roche Group	15,511	9	15,440	6	15,504	8	14,918	6	15,654	8

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2025 vs. YTD December 2024

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	7,010	9	4,874	7	1,451	13	-	-	685	21
Hemlibra	4,754	11	2,665	6	1,002	10	377	8	710	38
Vabysmo	4,102	12	2,857	3	741	21	146	22	358	116
Tecentriq	3,566	3	1,640	-2	878	3	349	-4	699	18
Xolair	3,075	32	3,075	32	-	-	-	-	-	-
Perjeta	2,968	-13	1,268	0	552	-13	69	-37	1,079	-21
Actemra/RoActemra	2,470	-2	1,206	-4	588	-9	310	5	366	16
Phesgo	2,441	48	708	31	812	12	188	44	733	172
Kadcyla	2,025	7	768	6	532	-4	91	-3	634	22
Evrysdi	1,757	13	612	10	616	9	90	1	439	25
Alecensa	1,562	6	565	14	262	-6	204	7	531	5
Polivy	1,470	38	688	28	290	53	207	9	285	87
MabThera/Rituxan	1,251	-4	794	0	140	-5	14	-11	303	-12
Activase/TNKase	1,107	-2	1,056	-2	-	-	-	-	51	-11
Herceptin	1,028	-22	225	-10	291	-2	7	-43	505	-32
Gazyva	986	14	519	19	245	2	35	25	187	15
Avastin	973	-17	299	-17	70	-16	145	-23	459	-14
Pulmozyme	479	12	343	20	65	-9	1	-12	70	1
Xofluza	407	184	57	66	2	*	-	-	348	219
CellCept	385	1	21	-5	131	8	44	17	189	-6
Enspryng	364	23	97	10	40	38	164	18	63	61
Elevidys	341	84	-	-	-	-	-	-	341	84
Columvi	288	75	178	88	62	66	-	-	48	49

Rozlytrek	146	14	47	-1	23	11	7	-16	69	36
Lunsumio	114	68	69	43	22	16	18	-	5	426
Itovebi	113	*	101	*	4	-	-	-	8	-
Cotellic	46	17	23	42	10	-5	-	-	13	4
PiaSky	46	200	-	59	7	*	38	165	1	-
Luxturna	41	146	41	146	-	-	-	-	-	-
Susvimo	9	132	9	132	-	-	-	-	-	-
Ronapreve	-	-100	-	-	-	-100	-	-	-	-100
Pharma other	2,345	-4	550	-9	328	-7	378	2	1,089	-3
Pharma total sales	47,669	9	25,355	8	9,164	5	2,882	5	10,268	14

* Over 500%

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Ocrevus	1,688	7	1,778	6	1,728	10	1,684	6	1,820	16
Hemlibra	1,223	21	1,165	11	1,256	22	1,105	4	1,228	8
Vabysmo	1,048	43	1,018	18	1,049	19	996	4	1,039	7
Tecentriq	937	-1	870	0	863	-1	883	4	950	8
Xolair	733	29	645	26	800	41	781	34	849	26
Perjeta	807	9	840	-10	773	-14	703	-14	652	-13
Actemra/RoActemra	697	4	619	-1	660	8	614	-2	577	-10
Phesgo	496	72	593	52	604	57	630	51	614	34
Kadcyla	504	9	506	5	531	12	494	7	494	6
Evrysdi	385	10	420	18	449	-1	424	10	464	26
Alecensa	397	8	397	11	405	6	388	8	372	1
Polivy	304	34	358	42	372	51	371	30	369	31
MabThera/Rituxan	356	-2	298	-16	332	1	303	3	318	-3
Activase/TNKase	307	15	297	-2	253	-7	283	1	274	-2
Herceptin	318	-10	292	-20	268	-23	257	-15	211	-29
Gazyva	240	25	249	15	241	12	238	13	258	15
Avastin	290	-17	274	-15	248	-19	241	-11	210	-21
Pulmozyme	126	18	123	10	116	13	122	26	118	1
Xofluza	53	-6	159	234	28	73	61	116	159	222
CellCept	116	23	98	4	98	1	96	18	93	-16

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Ocrevus	1,179	0	1,247	3	1,215	8	1,151	1	1,261	17
Hemlibra	748	20	610	0	714	21	617	-1	724	6
Vabysmo	794	35	718	7	732	10	689	-4	718	-1
Tecentriq	438	-5	411	-8	408	-4	403	2	418	4
Xolair	733	29	645	26	800	41	781	34	849	26
Perjeta	316	35	342	-3	335	4	291	-6	300	4
Actemra/RoActemra	382	12	294	3	325	11	307	-6	280	-19
Phesgo	166	64	179	38	169	40	175	29	185	22
Kadcyla	191	2	201	5	195	9	181	2	191	10
Evrysdi	159	29	160	15	149	10	159	18	144	0
Alecensa	153	23	130	21	146	19	144	15	145	4
Polivy	158	45	156	30	171	34	170	18	191	32
MabThera/Rituxan	227	2	181	-14	206	2	188	5	219	5
Activase/TNKase	290	16	285	-2	242	-5	270	1	259	-2
Herceptin	64	-12	60	-12	61	-8	54	-6	50	-14
Gazyva	130	34	131	27	122	14	123	14	143	20
Avastin	94	-17	80	-21	76	-18	69	-16	74	-14
Pulmozyme	90	23	84	22	83	22	87	30	89	8
Xofluza	31	235	14	239	3	*	15	*	25	-14
CellCept	6	-25	5	-5	4	-26	5	3	7	10

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Ocrevus	345	21	344	11	362	14	354	12	391	14
Hemlibra	236	15	247	7	246	7	247	14	262	12
Vabysmo	168	88	197	42	181	25	178	9	185	13
Tecentriq	214	0	220	5	214	1	216	0	228	7
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	144	-9	144	-16	138	-15	136	-14	134	-7
Actemra/RoActemra	150	-21	152	-19	156	-7	142	-1	138	-7
Phesgo	195	32	199	18	202	13	201	9	210	9
Kadcyla	136	5	135	-7	131	-5	130	-5	136	0
Evrysdi	137	3	145	6	147	3	158	7	166	21
Alecensa	67	-5	68	-6	65	-7	64	-10	65	-3
Polivy	50	38	94	74	66	119	68	21	62	26
MabThera/Rituxan	41	6	35	-10	35	-6	34	13	36	-13
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	76	-6	77	0	73	-2	73	2	68	-9
Gazyva	60	11	60	-3	61	4	62	1	62	5
Avastin	22	13	14	-33	12	-46	28	47	16	-22
Pulmozyme	18	-2	18	-9	16	-16	15	-3	16	-9
Xofluza	-	386	-	*	2	*	-	500	-	71
CellCept	43	51	34	7	31	17	32	49	34	-19

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	108	22	82	3	101	12	92	11	102	5
Vabysmo	39	46	32	35	38	28	35	17	41	15
Tecentriq	103	2	81	-5	93	-2	88	-1	87	-6
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	24	-53	18	-51	19	-35	17	-27	15	-31
Actemra/RoActemra	84	11	71	5	81	6	78	4	80	6
Phesgo	48	*	40	115	50	59	49	41	49	11
Kadcyla	27	10	21	-3	24	0	23	-2	23	-7
Evrysdi	27	9	20	0	26	9	22	7	22	-9
Alecensa	54	4	49	12	51	-1	51	13	53	7
Polivy	55	-3	44	2	55	14	54	14	54	5
MabThera/Rituxan	5	-22	3	-17	4	-12	4	-3	3	-11
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	3	-57	2	-56	2	-46	2	-30	1	-33
Gazyva	8	-10	8	46	9	3	8	22	10	37
Avastin	48	-28	36	-30	40	-21	35	-19	34	-21
Pulmozyme	-	32	-	-26	-	-11	-	13	1	-21
Xofluza	-	-	-	-	-	-	-	-	-	-
CellCept	13	13	12	38	12	33	10	13	10	-7

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024
Ocrevus	164	37	187	16	151	23	179	35	168	11
Hemlibra	131	36	226	72	195	60	149	9	140	18
Vabysmo	47	63	71	101	98	130	94	111	95	118
Tecentriq	182	5	158	21	148	7	176	17	217	25
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	323	9	336	-9	281	-27	259	-21	203	-30
Actemra/RoActemra	81	26	102	26	98	25	87	7	79	6
Phesgo	87	129	175	142	183	230	205	213	170	122
Kadcyla	150	25	149	21	181	33	160	28	144	9
Evrysdi	62	-9	95	56	127	-15	85	4	132	116
Alecensa	123	4	150	12	143	2	129	8	109	-3
Polivy	41	70	64	80	80	94	79	105	62	67
MabThera/Rituxan	83	-11	79	-23	87	2	77	-5	60	-22
Activase/TNKase	17	5	12	-9	11	-37	13	18	15	-4
Herceptin	175	-9	153	-29	132	-34	128	-25	92	-42
Gazyva	42	31	50	11	49	18	45	24	43	8
Avastin	126	-16	144	-3	120	-15	109	-13	86	-26
Pulmozyme	18	18	21	-10	17	7	20	34	12	-19
Xofluza	22	-53	145	234	23	42	46	73	134	*
CellCept	54	16	47	-4	51	-8	49	7	42	-18

* Over 500%

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

9. Roche Group consolidated income statement for the twelve months ended 31 December 2025

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	47,669	13,847	-	61,516
Other revenue	1,782	58	-	1,840
Cost of sales	(9,084)	(7,561)	-	(16,645)
Research and development	(11,300)	(2,052)	-	(13,352)
Selling, general and administration	(7,597)	(3,229)	(4,335)	(15,161)
Other operating income and expense	196	7	75	278
Operating profit	21,666	1,070	(4,260)	18,476
Financing costs				(1,349)
Other financial income (expense)				(154)
Profit before taxes				16,973
Income taxes				(3,174)
Net income				13,799
Attributable to				
- Roche shareholders				12,880
- Non-controlling interests				919
Earnings per share and non-voting equity security				
Basic (CHF)				16.18
Diluted (CHF)				16.04

10. Roche Group core results reconciliation – Full Year 2025

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	61,516	-	-	-	-	-	-	-	-	61,516
Other revenue	1,840	0	-	-	-	-	-	-	-	1,840
Cost of sales	(16,645)	315	366	100	0	-	-	-	-	(15,864)
Research and development	(13,352)	595	292	222	-	-	-	-	-	(12,243)
Selling, general and administration	(15,161)	1,312	11	0	-	-	-	-	-	(13,838)
Other operating income and expense	278	(58)	-	40	(8)	170	0	-	-	422
Operating profit	18,476	2,164	669	362	(8)	170	0	-	-	21,833
Financing costs	(1,349)	0	-	-	19	7	-	-	-	(1,323)
Other financial income (expense)	(154)	-	-	-	0	-	-	-	-	(154)
Profit before taxes	16,973	2,164	669	362	11	177	0	-	-	20,356
Income taxes	(3,174)	(441)	(116)	(66)	(15)	(24)	0	119	(64)	(3,781)
Net income	13,799	1,723	553	296	(4)	153	0	119	(64)	16,575
Attributable to										
- Roche shareholders	12,880	1,690	552	296	(4)	153	0	119	(64)	15,622
- Non-controlling interests	919	33	1	0	0	0	0	0	-	953
EPS - diluted (CHF)	16.04	2.11	0.69	0.37	(0.01)	0.19	-	0.15	(0.08)	19.46

11. Divisional core results reconciliation – Full Year 2025

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	47,669	-	-	-	-	-	-	47,669
Other revenue	1,782	0	-	-	-	-	-	1,782
Cost of sales	(9,084)	85	221	100	0	-	-	(8,678)
Research and development	(11,300)	389	290	222	-	-	-	(10,399)
Selling, general and administration	(7,597)	355	1	0	-	-	-	(7,241)
Other operating income and expense	196	(60)	-	0	(8)	179	0	307
Operating profit	21,666	769	512	322	(8)	179	0	23,440
Diagnostics								
Sales	13,847	-	-	-	-	-	-	13,847
Other revenue	58	0	-	-	-	-	-	58
Cost of sales	(7,561)	230	145	0	0	-	-	(7,186)
Research and development	(2,052)	206	2	0	-	-	-	(1,844)
Selling, general and administration	(3,229)	296	10	0	-	-	-	(2,923)
Other operating income and expense	7	2	-	40	0	(3)	0	46
Operating profit	1,070	734	157	40	-	(3)	0	1,998
Corporate								
Selling, general and administration	(4,335)	661	-	-	-	-	-	(3,674)
Other operating income and expense	75	0	-	-	0	(6)	0	69
Operating profit	(4,260)	661	-	-	0	(6)	0	(3,605)

12. Roche Group consolidated balance sheet

in millions of CHF	31 December 2025	31 December 2024	31 December 2023
Non-current assets			
Property, plant and equipment	21,949	22,557	21,724
Right-of-use assets	985	1,183	1,215
Goodwill	7,492	7,876	9,390
Intangible assets	19,321	17,303	14,828
Deferred tax assets	8,411	8,569	6,882
Defined benefit plan assets	1,791	2,256	1,019
Other non-current assets	2,025	2,021	1,964
Total non-current assets	61,974	61,765	57,022
Current assets			
Inventories	7,479	7,606	7,749
Accounts receivable	11,506	11,297	11,021
Current income tax assets	393	415	344
Other current assets	3,875	3,401	3,130
Marketable securities	9,894	10,342	5,134
Cash and cash equivalents	5,582	6,975	5,376
Assets held for sale	0	0	692
Total current assets	38,729	40,036	33,446
Total assets	100,703	101,801	90,468
Non-current liabilities			
Long-term debt	(27,430)	(30,722)	(24,809)
Net deferred tax liabilities	(884)	(832)	(593)
Defined benefit plan liabilities	(3,950)	(4,381)	(4,379)
Provisions	(1,055)	(1,079)	(1,059)
Other non-current liabilities	(1,503)	(1,603)	(1,541)
Total non-current liabilities	(34,822)	(38,617)	(32,381)
Current liabilities			
Short-term debt	(4,206)	(3,932)	(4,400)
Current income tax liabilities	(2,867)	(2,923)	(2,257)
Provisions	(1,743)	(1,726)	(1,684)
Accounts payable	(5,779)	(4,894)	(4,325)
Other current liabilities	(13,406)	(13,548)	(12,150)
Liabilities directly associated with assets held for sale	0	0	(8)
Total current liabilities	(28,001)	(27,023)	(24,824)
Total liabilities	(62,823)	(65,640)	(57,205)
Total net assets	37,880	36,161	33,263
Equity			
Capital and reserves attributable to Roche shareholders	33,802	31,767	29,315
Equity attributable to non-controlling interests	4,078	4,394	3,948
Total equity	37,880	36,161	33,263

13. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2025	FY 2024
Cash flows from operating activities		
Cash generated from operations	25,524	24,332
(Increase) decrease in net working capital	(1,657)	1,161
Payments made for defined benefit plans	(654)	(661)
Utilisation of provisions	(1,222)	(1,012)
Other operating cash flows	-	1
Cash flows from operating activities, before income taxes paid	21,991	23,821
Income taxes paid	(3,139)	(3,727)
Total cash flows from operating activities	18,852	20,094
Cash flows from investing activities		
Purchase of property, plant and equipment	(3,748)	(3,529)
Purchase of intangible assets	(2,031)	(1,480)
Disposal of property, plant and equipment	139	61
Disposal of intangible assets	2	-
Disposal of products	43	376
Business combinations and asset acquisitions	(3,078)	(3,119)
Divestment of subsidiaries	16	1
Interest and dividends received	167	232
Sales of marketable securities	241	198
Purchases of marketable securities	(263)	(112)
Sales (purchases) of money market instruments and time accounts over three months, net	54	(5,084)
Other investing cash flows	(85)	14
Total cash flows from investing activities	(8,543)	(11,393)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	2,299	7,915
Redemption and repurchase of bonds and notes	(3,386)	(3,095)
Increase (decrease) in commercial paper	656	(709)
Increase (decrease) in other debt	276	(292)
Hedging and collateral arrangements	(288)	30
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(1,189)	(1,145)
Principal portion of lease liabilities paid	(364)	(350)
Dividends paid	(8,385)	(8,043)
Equity-settled equity compensation plans, net of transactions in own equity	(987)	(1,130)
Other financing cash flows	-	-
Total cash flows from financing activities	(11,368)	(6,819)
Net effect of currency translation on cash and cash equivalents	(334)	(283)
Increase (decrease) in cash and cash equivalents	(1,393)	1,599
Cash and cash equivalents at beginning of period	6,975	5,376
Cash and cash equivalents at end of period	5,582	6,975